Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saurabh Sharma has a total of 192 co-authors. Here are the top co-authors by number of shared publications:

  • Deepak Chitkara

    Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus Vidya Vihar, Pilani, Rajasthan, India-333031

    9 shared publications
  • Anupama Mittal

    Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS-Pilani), Vidya Vihar, Pilani, Rajasthan - 333031, India

    7 shared publications
  • Surjendu Maity

    Terasaki Institute for Biomedical Innovation, Woodland Hills, CA, 91367, USA.; Department of Orthopedic Surgery, Duke University School of Medicine, Duke University, Durham, NC 27705, USA

    6 shared publications
  • Ali Khademhosseini

    Terasaki Institute for Biomedical Innovation, Los Angeles, CA 91367, USA

    5 shared publications
  • Anupama Mittal

    Department of Pharmacy Birla Institute of Technology and Science (BITS PILANI) Pilani Rajasthan 333031 India

    5 shared publications
  • Deepak Chitkara

    Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS), Pilani, India

    5 shared publications

Latest Publications

  • Predicting Targeted and Immunotherapeutic Response Outcomes in Melanoma With Single-Cell Raman Spectroscopy and Artificial Intelligence

    by Kai Chang, Mamatha Serasanambati, Baba Ogunlade, Hsiu-Ju Hsu, James Agolia, Ariel Stiber, Jeffrey Gu, Jay Chadokiya, Grayson E. Rodriguez, Prabhjeet Singh, et al.

    PURPOSE: Identifying reliable predictors of immunotherapeutic response in melanoma remains an outstanding challenge. Existing transcriptomic and proteomic profiling methods for the tumor-immune microenvironment are costly and may not faithfully capture modifications actively affecting tumor behavior. Here, we present a nondestructive, single-cell approach combining Raman spectroscopy and machine learning (ML) that enables rapid cell profiling and therapeutic response prediction. METHODS: We analyzed single-cell Raman spectra of mouse and human melanoma cell lines alongside nine samples derived from patients with melanoma with known resistance profiles to targeted and immunotherapeutic inhibitors bemcentinib, cabozantinib, dabrafenib, and nivolumab and a combination of nivolumab and relatlimab. We assessed cell phenotyping classification and treatment resistance using random forests and feature importance analysis. For patient samples, we constructed a two-stage evaluation workflow to determine clinical drug resistance through aggregated single-cell predictions and identified corresponding highly variant spectral signatures using computational methods adapted from single-cell RNA sequencing methods. RESULTS: In cell lines, our approach achieved >96% differentiation accuracy across tumor microenvironment cell types and induced functional phenotypes. Persistent (drug-resistant) cells formed subclusters based on genetic mutations rather than sample origin, with Raman signatures reflecting biochemical changes relevant to therapeutic pathways. For patient samples, our workflow correctly inferred resistance likelihoods for 30 of 33 clinically relevant patient-drug combinations (91% accuracy). CONCLUSION: Single-cell Raman spectroscopy combined with ML offers a scalable, prognostic platform to predict therapeutic resistance likelihood, with further potential to advance clinical, multiomic biomarker efforts for melanoma. Our approach may improve first- and second-line therapy selection assessments for precision medicine by providing rapid, nondestructive prediction of therapeutic response based on cellular spectral profiles.


  • Antibody-Free Immunopeptide Nanoconjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme

    by Saurabh Sharma, David Lee, Surjendu Maity, Prabhjeet Singh, Jay Chadokiya, Neda Mohaghegh, Alireza Hassani, Hanjun Kim, Ankit Gangarade, Julia Y. Ljubimova, et al.

    Glioblastoma Multiforme (GBM) represents a significant clinical challenge among central nervous system tumors, with a dismal mean survival rate of less than 8 months, a statistic that has remained largely unchanged for decades (National Brain Society, 2022). The specialized intricate anatomical features of the brain, notably the blood-brain barrier (BBB), pose significant challenges to effective therapeutic interventions, limiting the potential reach of modern advancements in immunotherapy to impact these types of tumors. This study introduces an innovative, actively targeted immunotherapeutic nanoconjugate (P-12/AP-2/NCs) designed to serve as an immunotherapeutic agent capable of traversing the BBB via LRP-1 receptor-mediated transcytosis. P-12/AP-2/NCs exert their immune-modulating effects by inhibiting the PD-1/PD-L1 axis through a small-sized PD-L1/PD-L2 antagonist peptide, Aurigene NP-12 (P-12). P-12/AP-2/NCs are synthesized from completely biodegradable, functionalized high molecular weight β-poly(l-malic acid) (PMLA) polymer conjugated with P-12 and Angiopep-2 (AP-2) to yield P-12/AP-2/NCs. Evaluating nanoconjugates for BBB permeability and 3D tumor model efficacy using an in vitro BBB-Transwell spheroid-based model demonstrated successful crossing of the BBB and internalization in brain 3D tumor environments. In addition, the nanoconjugate mediated T cells' cytotoxicity on 3D tumor region death in a U87 GBM 3D spheroid model. AP-2/P-12/NCs are selectively inhibited in PD1/PDL1 interaction on T cells and the tumor site, increasing inflammatory cytokine secretion and T cell proliferation. In an in vivo murine brain environment, rhodamine fluorophore-labeled AP-2/P-12/NCs displayed significantly increased accumulation in the brain during 2-6 h time intervals postinjection with a prolonged bioavailability over unconjugated peptides. AP-2/P-12/NCs demonstrated a safety profile at both low and high doses based on major organ histopathology evaluations. Our findings introduce a novel, programmable nanoconjugate platform capable of penetrating the BBB for directed delivery of small peptides and significant immune environment modulation without utilizing antibodies, offering promise for treating challenging brain diseases such as glioblastoma multiforme and beyond.


  • Open Access

    Recent Advancements Towards the Use of Vitamin D Isoforms and the Development of Their Synthetic Analogues as New Therapeutics

    by Rajiv Patel, Nandini, Harsha Kharkwal, Moumita Saha, Murugesan Sankaranarayanan, Saurabh Sharma, Subhash Chander

    Vitamin D and its metabolites are essential in various physiological processes, including muscle strength, metabolism, antifibrotic activity, and immune regulation. Researchers are focusing on developing vitamin D derivatives with optimized receptor selectivity and reduced systemic toxicity, enhancing their therapeutic efficacy against cancer, autoimmune disorders, and inflammatory diseases. Several analogues, such as alfacalcidol, paricalcitol, and falecalcitriol, are used for managing CKD-related bone disorders, while eldecalcitol is effective for osteoporosis, and calcipotriol against psoriasis. Recent studies have explored their impact on metabolic pathways, parathyroid hormone secretion, asthma, and liver fibrosis, revealing their broad clinical potential. Despite enormous efforts in the past decades, translations of vitamin D-drugs are disproportionately limited, mainly due to toxicity due to calcemic effects and undesirable metabolic profile. This review discusses structural modifications in vitamin D3, their influence on VDR binding, transcriptional activity, and calcium homeostasis, along with their role in targeting pathways like EGFR, KRAS, and Hedgehog in cancers. Advanced analytical techniques such as LC/ESI-MS/MS facilitate precise detection of vitamin D metabolites, further improving pharmacokinetic profiling. Future research may enable the clinical approval of novel vitamin D-based therapeutics with minimal disruption to calcium–phosphorus balance.


  • Open Access

    Antibody-Free Immunopeptide Nano-Conjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme

    by Saurabh Sharma, David Lee, Surjendu Maity, Prabhjeet Singh, Jay Chadokiya, Neda Mohaghegh, Alireza Hassani, Hanjun Kim, Ankit Gangarade, Julia Y. Ljubimova, et al.

    Glioblastoma Multiforme (GBM) represents a significant clinical challenge amongst central nervous system (CNS) tumors, with a dismal mean survival rate of less than 8 months, a statistic that has remained largely unchanged for decades (National Brain Society, 2022). The specialized intricate anatomical features of the brain, notably the blood-brain barrier (BBB), pose significant challenges to effective therapeutic interventions, limiting the potential reach of modern advancements in immunotherapy to impact these types of tumors. This study introduces an innovative, actively targeted immunotherapeutic nanoconjugate (P12/AP-2/NCs) designed to serve as an immunotherapeutic agent capable of traversing the BBB via LRP-1 receptor-mediated transcytosis. P12/AP-2/NCs exert its immune-modulating effects by inhibiting the PD-1/PD-L1 axis through a small-size PD-L1/ PD-L2 antagonist peptide Aurigene NP-12 (P12). P12/AP-2/NCs are synthesized from completely biodegradable, functionalized high molecular weight β-poly(L-malic acid) (PMLA) polymer, conjugated with P12 and Angiopep-2 (AP2) to yield P12/AP-2/NCs. Evaluating nanoconjugates for BBB permeability and 3-D tumor model efficacy using an in vitro BBB-Transwell spheroid based model demonstrating successful crossing of the BBB and internalization in brain 3D tumor environments. In addition, the nanoconjugate mediated T cell’s cytotoxicity on 3D tumor region death in a U87 GBM 3-D spheroid model. AP2/P12/NCs is selectively inhibited in PD1/PDL1 interaction on T cells and tumor site, increasing inflammatory cytokine secretion and T cell proliferation. In an in-vivo murine brain environment, rhodamine fluorophore-labeled AP2/P12/NCs displayed significantly increased accumulation in the brain during 2-6 h time intervals post-injection with a prolonged bioavailability over unconjugated peptides. AP2/P12/NCs demonstrated a safety profile at both low and high doses based on major organ histopathology evaluations. Our findings introduce a novel, programmable nanoconjugate platform capable of penetrating the BBB for directed delivery of small peptides and significant immune environment modulation without utilizing antibodies, offering promise for treating challenging brain diseases like glioblastoma multiforme and beyond.


  • Open Access

    Smart biomaterials in healthcare: Breakthroughs in tissue engineering, immunomodulation, patient-specific therapies, and biosensor applications

    by Ansheed Raheem, Kalpana Mandal, Swarup Biswas, Amir Ahari, Alireza Hassani Najafabadi, Neda Farhadi, Fatemeh Zehtabi, Ankit Gangrade, Marvin Mecwan, Surjendu Maity, et al.

    Smart biomaterials have significantly impacted human healthcare by advancing the development of medical devices designed to function within human tissue, mimicking the behavior of natural tissues. While the intelligence of biomaterials has evolved from inert to active over the past few decades, smart biomaterials take this a step further by making their surfaces or bulk respond based on interactions with surrounding tissues, imparting outcomes similar to natural tissue functions. This interaction with the surrounding tissue helps in creating stimuli-responsive biomaterials, which can be useful in tissue engineering, regenerative medicine, autonomous drug delivery, orthopedics, and much more. Traditionally, material engineering focused on refining the static properties of biomaterials to accommodate them within the body without evoking an immune response, which was a major obstacle to their unrestricted operation. This review highlights and explains various engineering approaches currently under research for developing stimuli-responsive biomaterials that tune their outcomes based on responses to bodily factors like temperature, pH, and ion concentration or external factors like magnetism, light, and conductivity. Applications in soft and hard tissue engineering, 4D printing, and scaffold design are also discussed. The advanced application of microfluidics, like organ-on-a-chip models, extensively benefits from the intrinsic smart properties of biomaterials, which are also discussed below. The review further elaborates on how smart biomaterial engineering could revolutionize biosensor applications, thereby improving patient care quality. We delineate the limitations and key challenges associated with biomaterials, providing insights into the path forward and outlining future directions for developing next-generation biomaterials that will facilitate clinical translation.


  • Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment

    by Amanda R. Kirane, David Lee, Michael Lowe, M. Usman Ahmad, Saurabh Sharma, Mamatha Serasanambati, Christopher J. Applebee, Elena Safrygina, Allison Betof Warner, Jennifer Wang, et al.

    PURPOSE: Despite the effectiveness of immunotherapy in advanced melanoma, the lack of clinically reliable biomarkers hinders precision medicine approaches. This study investigates the potential of immune time-resolved Förster resonance energy transfer (iFRET) as a novel tool for understanding immunotherapy response in melanoma. METHODS: Using tissue from a pilot phase II study of neoadjuvant talimogene laherparepvec (TVEC) before standard surgery, we explore iFRET's ability to assess PD-L1:PD-1 interactions in the tumor immune microenvironment (TiME) pre- and post-therapy. RESULTS: Responsive tumors demonstrated significant increases in iFRET efficiency, diverging from nonresponsive tumors that either decreased in checkpoint engagement or failed to demonstrate immune stimulation with therapy. Changes in PD-L1:PD-1 iFRET efficiency did not correlate with changes in PD-L1 expression. Instead, traditional biomarkers of PD-L1 expression and T-cell phenotyping did not reflect response trends and demonstrated significant heterogeneity inter- and intratumorally. Importantly, tumor-associated macrophage phenotype correlated significantly with TVEC response and the significantly high PD-L1:PD-1 interaction observed in the tumor beds of complete responders. CONCLUSION: These findings underscore both the role of innate immune profiles in immunotherapy outcomes and the potential of iFRET to serve as a critical companion diagnostic in the classification of immune profiles. This research reveals crucial insights into factors affecting checkpoint function in tumors and emphasizes the need for further investigation into cell-specific interactions within the TiME. By expanding our understanding of distinct patient profiles for tailored therapeutic strategies, we underscore the importance of assessing this type of functional biomarker data in ongoing neoadjuvant trial designs to advance the goal of precision immunotherapy in patients with melanoma.


  • Recent Developments in Glioblastoma‐On‐A‐Chip for Advanced Drug Screening Applications

    by Surjendu Maity, Tamanna Bhuyan, Christopher Jewell, Satoru Kawakita, Saurabh Sharma, Huu Tuan Nguyen, Alireza Hassani Najafabadi, Menekse Ermis, Natashya Falcone, Junjie Chen, et al.

    Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood‐brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ‐on‐a‐chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM‐on‐a‐chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM‐on‐a‐chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM‐on‐a‐chip models.


  • Open Access

    The Utilisation of Mushroom Leftovers, Oats, and Lactose-Free Milk Powder for the Development of Geriatric Formulation

    by Snigdha Paul, Ravinder Kaushik, Shuchi Upadhyay, Ansab Akhtar, Prince Chawla, Naveen Kumar, Saurabh Sharma, Pooja Rani

    This study aims to focus on developing a food supplement for the geriatric population using disposal mushrooms, oats, and lactose-free milk powder. Lactose intolerance is most common in older adults, raising the demand for lactose-free foods. One of the major global challenges currently faced by humankind is food waste (FW). Most of the food that is produced for human consumption has not been utilized completely (1/3rd–1/2 unutilized), resulting in agricultural food waste. Mushrooms are highly valuable in terms of their nutritional value and medicinal properties; however, a significant percentage of mushroom leftovers are produced during mushroom production that do not meet retailers’ standards (deformation of caps/stalks) and are left unattended. Oats are rich in dietary fibre beta-glucan (55% water soluble; 45% water insoluble). Lactose-free milk powder, oats, and dried mushroom leftover powder were blended in different ratios. It was observed that increasing the amount of mushroom leftover powder increases the protein content while diluting calories. The product with 15% mushroom powder and 30% oat powder showed the highest sensory scores and the lowest microbial count. The GCMS and FTIR analyses confirmed the presence of ergosterol and other functional groups. The results of the XRD analysis showed that the product with 15% mushroom powder and 30% oat powder had a less crystalline structure than the product with 5% mushroom powder and 40% oat powder and the product with 10% mushroom powder and 35% oat powder, resulting in more solubility. The ICP-OES analysis showed significant concentrations of calcium, potassium, magnesium, sodium, and zinc. The coliform count was nil for the products, and the bacterial count was below the limited range (3 × 102 cfu/g). The product with 15% mushroom powder and 30% oat powder showed the best results, so this developed product is recommended for older adults.


  • Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer

    by Saurabh Sharma, Rajesh Pradhan, David Lee, Mahalaxmi Sharma, Shima Zahed Nasab, Siddhanth Hejmady, Subhash Chander, Neda Mohaghegh, Surjendu Maity, Shahid Khan, et al.

    Triple‐negative breast cancer develops from malignant cells within the interior lining of milk ducts or, less frequently, in the stromal tissues and accounts for ≈15% of all breast cancers. Breast cancer is highly prevalent with the overall number of cases expected to reach 27.78 million by 2040, according to the World Health Organization. MiRNAs serve a novel role in management of breast cancer through their ability to indirectly control the translation of coding mRNA and regulate the expression of specific genes, which allows it to play a significant role in cancer therapeutics. However, inherent characteristics of miRNA including rapid clearance via renal excretion, degradation by nucleases in plasma, and additional factors limit its clinical application. To reduce these limitations, miRNA can be administered in conjunction small molecules with nanocarriers, which then allow it to impart its benefits including inhibition of epithelial–mesenchymal transitions, and inhibiting tumor angiogenesis. This review highlights the current application of nanocarrier‐based delivery approach of miRNA/siRNA for triple negative breast cancer treatment.


  • Open Access

    Phenylthiazolidin-4-one piperazine Conjugates: Design, Synthesis, anticancer and antimicrobial studies

    by Dalbir Singh, Rajiv Patel, Amit Aggarwal, Anwesha Das, Saurabh Sharma, Birasen Behera, Rajashree Panigrahy, Amanda R. Kirane, Harsha Kharkwal, Piyush Kumar, et al.